Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables

BACKGROUND: Prostate Cancer (PCa) represents the second leading cause of cancer-related death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa screening, lacks the necessary sensitivity and specificity. New non-invasive diagnostic tools able to discriminate tumoral from...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabriele, Caterina, Aracri, Federica, Prestagiacomo, Licia Elvira, Rota, Maria Antonietta, Alba, Stefano, Tradigo, Giuseppe, Guzzi, Pietro Hiram, Cuda, Giovanni, Damiano, Rocco, Veltri, Pierangelo, Gaspari, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662699/
https://www.ncbi.nlm.nih.gov/pubmed/37990292
http://dx.doi.org/10.1186/s12014-023-09439-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662699/
https://www.ncbi.nlm.nih.gov/pubmed/37990292
http://dx.doi.org/10.1186/s12014-023-09439-4

Ejemplares similares